Liminatus Pharma, Inc. Class A Common Stock
LIMNNASDAQHealthcareBiotechnology
Previous close
$5.16
−$0.47 · -8.35%
Pre-market
$5.15
−$0.01 · -0.19%
Aug 24, 8:43 AM ET
LIMN company overview
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
60
Fair Value
Momentum
17
Strong Down
Sentiment
51
Mixed
Risk resilience
34
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteLiminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Chris Kim
- Listed since
- May 1, 2025
- Employees
- 1
Market position
Day range
Current $5.16
52-week range
Current $5.16
- Open
- $5.53
- Previous close
- $5.63
- Volume
- 116.54K
- 0.19× average
- Average volume
- 603.45K
- Average daily volume
- Market cap
- 6.93M USD
- Beta
- 0.74
- Market reference 1
- 50-day average
- $5.8422
- -11.68% below average
- 200-day average
- $21.1968
- -75.66% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 15.59M USD
- EV / EBITDA
- -1.56×
- Earnings yield
- -70.44%
- Free cash flow yield
- -68.85%
Profitability & efficiency
- Return on equity
- 103.99%
- Return on assets
- -1990.37%
- Return on invested capital
- 35.57%
Financial health
- Current ratio
- 0.05×
- Altman Z-score
- -27.62
- Piotroski F-score
- 2 of 9
Earnings
- Latest fiscal-year EPS
- -21.5
- FY2025
- Latest fiscal-year revenue
- 0 USD
- FY2025
Annual EPS trend
Reported history and fiscal-year consensus
Annual revenue trend
Reported history and fiscal-year consensus
LIMN news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 21, 2026 | 1:50 | — | — |
Effective Aug 21, 2026
1:50
LIMN peers
Continue in GoAI
Research LIMNresearch.disclaimer